Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Multimodality treatment of osteosarcoma of the jaw : a single institution experience

Title: Multimodality treatment of osteosarcoma of the jaw : a single institution experience
Authors: D. Ferrari; S. Caldiera; C. Codecà; N. Battisti; F. Broggio; F. Crepaldi; M. Violati; C. Bertuzzi; L. Dottorini; A. Luciani; L. Moneghini; F. Biglioli; G. Cassinelli; A. Morabito; P. Foa
Contributors: D. Ferrari; C. Codecà; N. Battisti; F. Broggio; F. Crepaldi; M. Violati; C. Bertuzzi; L. Dottorini; S. Caldiera; A. Luciani; L. Moneghini; F. Biglioli; G. Cassinelli; A. Morabito; P. Foa
Publisher Information: Humana Press
Publication Year: 2014
Collection: The University of Milan: Archivio Istituzionale della Ricerca (AIR)
Subject Terms: adjuvant radiotherapy; chemotherapy; chemotherapy-induced necrosi; head–neck cancer; jaw osteosarcoma; reconstructive surgery; adolescent; adult; aged; antineoplastic agent; chemoradiotherapy; adjuvant; disease-free survival; female; human; jaw neoplasm; kaplan-meier estimate; male; middle aged; osteosarcoma; prognosi; reconstructive surgical procedure; retrospective studie; young adult; oncology; cancer research; hematology; Settore MED/06 - Oncologia Medica
Description: Osteosarcomas of the jaws are rare mesenchymal tumors frequently diagnosed in the fourth decade of life which account for 6 % of all osteosarcomas. This study evaluated the efficacy on the patients outcome of multimodality treatment consisting of surgery, chemotherapy and radiotherapy. The records of 22 patients affected by jaw osteosarcoma treated with a combination of surgery, poly-chemotherapy and adjuvant radiotherapy in selected cases were reviewed. Response rate, progression-free survival and overall survival were evaluated. Neoadjuvant chemotherapy resulted in an overall response rate of 83.3 %, necrosis of grade I or II was obtained, respectively, in 44.4 and 55.6 % of the patients, and surgery was radical in all patients. At a median follow-up of 60 months, the 5-year progression-free survival and overall survival were 73.5 and 77.4 %, respectively. These outcome parameters significantly correlated with age at diagnosis and grade of chemotherapy-induced necrosis. A complex multimodality approach including chemotherapy and radiotherapy, along with radical surgery, can maximize the outcome of patients affected by osteosarcoma of the jaws.
Document Type: article in journal/newspaper
Language: English
Relation: info:eu-repo/semantics/altIdentifier/pmid/25134917; info:eu-repo/semantics/altIdentifier/wos/WOS:000341835700043; volume:31; issue:9; firstpage:1; lastpage:7; numberofpages:7; journal:MEDICAL ONCOLOGY; https://hdl.handle.net/2434/427071
DOI: 10.1007/s12032-014-0171-9
Availability: https://hdl.handle.net/2434/427071; https://doi.org/10.1007/s12032-014-0171-9
Rights: info:eu-repo/semantics/closedAccess
Accession Number: edsbas.51722AE2
Database: BASE